[
  {
    "date": "2023-12-30",
    "symbol": "BRNS",
    "period": "FY",
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documentperiodenddate": "2023-12-31",
    "currentfiscalyearenddate": "--12-31",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-40367",
    "entityregistrantname": "BARINTHUS BIOTHERAPEUTICS PLC",
    "entityincorporationstatecountrycode": "X0",
    "entitytaxidentificationnumber": "00-0000000",
    "entityaddressaddressline1": "Unit 6-10, Zeus Building",
    "entityaddressaddressline2": "Rutherford Avenue",
    "entityaddresscityortown": "Harwell,Didcot",
    "entityaddresspostalzipcode": "OX11 0DF",
    "entityaddresscountry": "GB",
    "cityareacode": "+44 (0)",
    "localphonenumber": "1865 818 808",
    "security12btitle": "American Depositary Shares",
    "tradingsymbol": "BRNS",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityshellcompany": "false",
    "entitycentralindexkey": 1828185,
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "auditorfirmid": 876,
    "auditorname": "PricewaterhouseCoopers LLP",
    "auditorlocation": "United Kingdom",
    "cashandcashequivalentsatcarryingvalue": 142090000,
    "researchanddevelopmentincentivesreceivable": 4908000,
    "prepaidexpenseandotherassetscurrent": 9907000,
    "assetscurrent": 156905000,
    "goodwill": 12209000,
    "propertyplantandequipmentnet": 11821000,
    "intangibleassetsnetexcludinggoodwill": 25108000,
    "operatingleaserightofuseasset": 7581000,
    "otherassets": 882000,
    "assets": 214506000,
    "accountspayablecurrent": 1601000,
    "accruedliabilitiesandotherliabilitiescurrent": 9212000,
    "operatingleaseliabilitycurrent": 1785000,
    "liabilitiescurrent": 12598000,
    "operatingleaseliabilitynoncurrent": 11191000,
    "businesscombinationcontingentconsiderationliabilitynoncurrent": 1823000,
    "otherliabilitiesnoncurrent": 1325000,
    "deferredtaxliabilitynet": 574000,
    "liabilities": 27511000,
    "commonstockvalue": 1000,
    "deferredstockvalueissued": 86000,
    "additionalpaidincapital": 386602000,
    "retainedearningsaccumulateddeficit": -176590000,
    "accumulatedothercomprehensiveincomelossforeigncurrencytranslationadjustmentnetoftax": -23315000,
    "stockholdersequity": 186784000,
    "minorityinterest": 211000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": 186995000,
    "liabilitiesandstockholdersequity": 214506000,
    "commonstockparorstatedvaluepershare": 0.000025,
    "commonstocksharesauthorized": 38643540,
    "commonstocksharesissued": 38643540,
    "commonstocksharesoutstanding": 38643540,
    "deferredstockparorstatedvaluepershare": 1,
    "deferredstocksharesauthorized": 63443,
    "deferredstocksharesissued": 63443,
    "deferredstocksharesoutstanding": 63443,
    "revenuefromcontractwithcustomerexcludingassessedtax": 802000,
    "researchanddevelopmentexpense": 44874000,
    "generalandadministrativeexpense": 39842000,
    "operatingexpenses": 84716000,
    "operatingincomeloss": -83914000,
    "investmentincomeinterest": 2877000,
    "interestexpense": 28000,
    "researchanddevelopmentincentiveincomeexpense": 3461000,
    "othernonoperatingincomeexpense": 1082000,
    "nonoperatingincomeexpense": 7392000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -76522000,
    "incometaxexpensebenefit": -3075000,
    "profitloss": -73447000,
    "netincomelossattributabletononcontrollinginterest": -100000,
    "netincomeloss": -73347000,
    "weightedaveragenumberofsharesoutstandingbasic": 38386491,
    "weightedaveragenumberofdilutedsharesoutstanding": 38386491,
    "earningspersharebasic": -1.91,
    "earningspersharediluted": -1.91,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 10151000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -63296000,
    "comprehensiveincomenetoftaxattributabletononcontrollinginterest": -94000,
    "comprehensiveincomenetoftax": -63202000,
    "revenuefromcontractwithcustomerproductandserviceextensiblelist": "http://fasb.org/us-gaap/2023#LicenseMember",
    "sharesissued": 38643540,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 5055000,
    "stockissuedduringperiodsharesother": 960009,
    "stockissuedduringperiodvalueother": 2035000,
    "sharescancelledduringperiodsharesdeferredshares": 570987,
    "sharescancelledduringperiodvaluedeferredshares": 8000,
    "sharebasedcompensation": 5055000,
    "depreciationdepletionandamortization": 5429000,
    "noncashleaseexpenses": 1328000,
    "foreigncurrencytransactiongainlossunrealized": -7531000,
    "businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsiderationliability1": 55000,
    "noncashinterestexpenseonconvertibleloannotes": 28000,
    "deferredincometaxexpensebenefit": -3075000,
    "increasedecreaseinaccountsreceivable": -5800000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -2200000,
    "increasedecreaseinresearchanddevelopmentincentivesreceivable": 127000,
    "increasedecreaseinaccountspayable": -3378000,
    "increasedecreaseinaccruedliabilitiesandotheroperatingliabilities": 1993000,
    "increasedecreaseinoperatingleaseliability": -445000,
    "increasedecreaseinotheroperatingassets": -128000,
    "netcashprovidedbyusedinoperatingactivities": -50925000,
    "paymentstoacquirepropertyplantandequipment": 5413000,
    "netcashprovidedbyusedininvestingactivities": -5413000,
    "proceedsfromissuanceofcommonstock": 2035000,
    "paymentforcontingentconsiderationliabilityfinancingactivities": 163000,
    "netcashprovidedbyusedinfinancingactivities": 1872000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 2171000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -52295000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 142090000,
    "capitalexpendituresincurredbutnotyetpaid": 87000,
    "assetretirementobligations": 287000,
    "changestorightofuseassetresultingfromleasereassessmentevent": 88000,
    "prepaidexpenseandotherassetscurrenttextblock": "Prepaid and other current assets",
    "accruedliabilitiesandothercurrentliabilitiestextblock": "Accrued Expenses and Other Current Liabilities",
    "stockholdersequitydeferredsharesdisclosuretextblock": "Deferred shares",
    "clinicaltrialcostspolicytextblock": "Clinical trial costsClinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.",
    "additionalpaidincapitalpolicytextblock": "Additional paid-in capitalAdditional paid-in capital is classified in stockholders’ equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.",
    "researchanddevelopmentincentivespolicytextblock": "Research and development incentives",
    "accruedliabilitiesandothercurrentliabilitiestabletextblock": "Accrued expenses and other current liabilities consist of the following (in thousands):December 31,2023December 31,2022Accrued manufacturing and clinical expenses$4,003 $2,997 Accrued bonus2,412 1,925 Accrued payroll and employee benefits789 928 Accrued professional fees942 1,270 Accrued other1,066 941 Total$9,212 $8,061",
    "contractwithcustomerliabilitiestabletextblock": "Changes in the contract liabilities during the years ended December 31, 2023 and 2022, are as follows (in thousands):December 31,2023December 31,2022Beginning balance$— $182 Revenue recognized related to contract liability balance— (158)Foreign exchange translation— (24)Ending balance$— $—",
    "scheduleofordinarysharesreservedforfutureissuancetabletextblock": "As of December 31, 2023, the Company has reserved the following ordinary shares for future issuance:Exercise of stock options6,207,664Shares available for future stock incentive plan awards1,623,840Total7,831,504",
    "lesseeoperatingleaserightofuseassetandotherinformationtabletextblock": "The Company’s right-of-use assets and lease liabilities are as follows (in thousands):",
    "foreigncurrencytransactiongainlossbeforetax": -7600000,
    "numberofoperatingsegments": 1,
    "accountsreceivablestandardpaymenttermsperiod": "P30D",
    "concentrationriskthresholdpercentage": 1,
    "propertyplantandequipmentusefullife": "P3Y",
    "finitelivedintangibleassetusefullife": "P10Y",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 6207664,
    "propertyplantandequipmentgross": 1108000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 3688000,
    "depreciation": 2300000,
    "finitelivedintangibleassetsgross": 31600000,
    "finitelivedintangibleassetsaccumulatedamortization": 6500000,
    "amortizationofintangibleassets": 3200000,
    "finitelivedintangibleassetsamortizationexpensenexttwelvemonths": 3200000,
    "finitelivedintangibleassetsamortizationexpenseyeartwo": 3200000,
    "finitelivedintangibleassetsamortizationexpenseyearthree": 3200000,
    "finitelivedintangibleassetsamortizationexpenseyearfour": 3200000,
    "finitelivedintangibleassetsamortizationexpenseyearfive": 3200000,
    "finitelivedintangibleassetexpectedamortizationyearsix": 3200000,
    "finitelivedintangibleassetexpectedamortizationyearseven": 3200000,
    "finitelivedintangibleassetexpectedamortizationyeareight": 3200000,
    "prepaidexpensecurrent": 5402000,
    "valueaddedtaxreceivablecurrent": 3031000,
    "otherassetscurrent": 1474000,
    "accruedmanufacturingandclinicalexpensescurrent": 4003000,
    "accruedbonusescurrent": 2412000,
    "accruedemployeebenefitscurrent": 789000,
    "accruedprofessionalfeescurrent": 942000,
    "otheraccruedliabilitiescurrent": 1066000,
    "commonstocknumberofvotespershare": 1,
    "percentageofsharesnecessarytoexercisepreemptiverights": 0.75,
    "periodofpreemptiverightstobeexercised": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 6207664,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 1623840,
    "commonstockcapitalsharesreservedforfutureissuance": 7831504,
    "ordinarysharesliquidationpreference": 1000000,
    "fairvaluemeasurementwithunobservableinputsreconciliationsrecurringbasisliabilityvalue": 1800000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitygainlossincludedinearnings": -55000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitysettlements": 163000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilityforeignexchangetranslation": 219000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.99,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 200000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 3000000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P1Y7M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.971,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.037,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 2288236,
    "stockissuedduringperiodsharesstockoptionsexercised": 72386,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 892906,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 2839791,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 6.91,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.51,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 0.00026,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 7.3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 8.91,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P7Y11M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P7Y3M29D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 6044000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 2883000,
    "allocatedsharebasedcompensationexpense": 2011000,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -50534000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -24507000,
    "currentforeigntaxexpensebenefit": 28000,
    "deferredforeignincometaxexpensebenefit": -3148000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.2352,
    "effectiveincometaxratereconciliationnondeductibleexpense": 0.0103,
    "effectiveincometaxratereconciliationprovisiontoreturnadjustments": -0.0409,
    "effectiveincometaxratereconciliationtaxcreditsresearchanddevelopment": 0.0494,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": 0.0123,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.1184,
    "effectiveincometaxratereconciliationsharebasedcompensationexcesstaxbenefitpercent": -0.0084,
    "effectiveincometaxratecontinuingoperations": 0.0407,
    "deferredtaxassetsoperatinglosscarryforwards": 23589000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 40000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 4226000,
    "deferredtaxassetsleasingarrangements": 3404000,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsintangibles": 745000,
    "deferredtaxassetsinprocessresearchanddevelopment": 4228000,
    "deferredtaxassetsother": 1000,
    "deferredtaxassetsgross": 36233000,
    "deferredtaxassetsvaluationallowance": 25057000,
    "deferredtaxassetsnet": 11176000,
    "deferredtaxliabilitiespropertyplantandequipment": 1652000,
    "deferredtaxliabilitiesleasingarrangements": 1922000,
    "deferredtaxliabilitiesunrealizedgainsontradingsecurities": 1267000,
    "deferredtaxliabilitiesgoodwillandintangibleassetsintangibleassets": 6909000,
    "deferredincometaxliabilitiesnet": 11750000,
    "deferredtaxliabilities": 574000,
    "operatinglosscarryforwards": 92700000,
    "taxcreditcarryforwardamount": 40000,
    "valuationallowancedeferredtaxassetincreaseresultingfromcurrentperiodadditions": 1052000,
    "valuationallowancedeferredtaxassetincreaseresultingfromincometaxprovision": 9605000,
    "valuationallowancedeferredtaxassetincreasedecreaseresultingfromforeigncurrencytranslation": 693000,
    "percentageoffutureroyaltiesfordirectsalesofcoveredproductlicenseagreement": 0.01,
    "percentageofnetpaymentsreceivedforallowablesublicensesoftechnologydevelopedlicenseagreement": 0.03,
    "operatingleasepayments": 639000,
    "operatingleaseweightedaverageremainingleaseterm1": "P8Y11M4D",
    "operatingleaseweightedaveragediscountratepercent": 0.075,
    "shorttermleasecost": 189000,
    "operatingleasecost": 883000,
    "leasecost": 1072000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1785000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1936000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 1960000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 1985000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 2010000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 7999000,
    "lesseeoperatingleaseliabilitypaymentsdue": 17675000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 4699000,
    "operatingleaseliability": 12976000,
    "definedcontributionplanemployerdiscretionarycontributionamount": 700000,
    "relatedpartytransactionamountsoftransaction": 400000
  }
]